ClearPoint Neuro Q3 revenue misses estimates

Overview

• US neuro device maker's Q3 revenue rose 36% yr/yr, driven by IRRAflow and biologics growth

• Gross margin fell to 58% from 63% due to new lab overhead and amortization costs

• Company raised $22 mln from equity offering, ending Q3 with $46.2 mln in cash

Outlook

• Company now estimates 2026 revenue to be between $48.0 mln and $50.0 mln

Result Drivers

• IRRAFLOW ACQUISITION - Revenue growth in neurosurgery navigation and therapy was primarily driven by additional sales from the acquired IRRAflow product

• CAPITAL EQUIPMENT SALES - Record capital equipment and software revenue reflected increased placements of navigation, IRRAflow control units, and Prism laser units

• LAB SERVICES DEMAND - Biologics and drug delivery revenue rose mainly due to higher revenue from services performed at ClearPoint Advanced Laboratories

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for Clearpoint Neuro Inc is $23.50, about 142.5% above its October 27 closing price of $9.69

Reuters Recommended Reads

• Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

• Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment

• Oct 28 - AxoGen Q3 revenue beats estimates on market expansion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)